These therapies include imatinib mesylate (IM), a non-selective receptor tyrosine kinase inhibitor (RTKi), which is used as the first-line therapy for GIST patients, with a reported response rate (RR) of ~50–70% and progression-free survival (PFS) of ~20 months [4,5,6]. Here, NTRK1 is linked to gastrointestinal stromal tumor.